



## BioCryst to Report Fourth Quarter 2022 Financial Results on February 21

February 7, 2023

RESEARCH TRIANGLE PARK, N.C., Feb. 07, 2023 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2022 financial results on Tuesday, February 21, 2023.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-866-777-2509 for domestic callers and 1-412-317-5413 for international callers. A live webcast and replay of the call will be available online at the investors section of the company website at [www.biocryst.com](http://www.biocryst.com).

### **About BioCryst Pharmaceuticals**

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO<sup>®</sup> (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB<sup>®</sup> (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company's website at [www.biocryst.com](http://www.biocryst.com).

BCRXW

### **Investor Contact:**

John Bluth  
+1 919 859 7910  
[jbluth@biocryst.com](mailto:jbluth@biocryst.com)

### **Media Contact:**

Catherine Collier Kyroulis  
+1 917 886 5586  
[ckyroulis@biocryst.com](mailto:ckyroulis@biocryst.com)